BACKGROUND. Inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, are now used frequently to treat hypercholesterolemia. We studied the effects of specific inhibition of cholesterol synthesis by one of these agents (pravastatin) on the hepatic metabolism of cholesterol in patients with gallstone disease who were scheduled to undergo cholecystectomy. METHODS. Ten patients were treated with pravastatin (20 mg twice a day) for three weeks before cholecystectomy; 20 patients not treated served as controls. A liver specimen was obtained from each patient at operation, and the activities of rate-determining enzymes in cholesterol metabolism as well as low-density-lipoprotein (LDL)-receptor binding activity were determined. RESULTS. Pravastatin therapy reduced plasma total cholesterol by 26 percent and LDL cholesterol by 39 percent (P less than 0.005). Serum levels of free lathosterol, a precursor of cholesterol whose concentration reflects the rate of cholesterol synthesis in vivo, decreased by 63 percent (P less than 0.005), indicating reduced de novo biosynthesis of cholesterol. Microsomal HMG-CoA reductase activity, when analyzed in vitro in the absence of the inhibitor, was increased 11.8-fold (1344 +/- 311 vs. 105 +/- 14 pmol per minute per milligram of protein in the controls; P less than 0.001). The expression of LDL receptors was increased by 180 percent (P less than 0.005), whereas the activities of cholesterol 7 alpha-hydroxylase (which governs bile acid synthesis) and of acyl-coenzyme A:cholesterol O-acyltransferase (which regulates cholesterol esterification) were unaffected by treatment. CONCLUSIONS. Inhibition of hepatic HMG-CoA reductase by pravastatin results in an increased expression of hepatic LDL receptors, which explains the lowered plasma levels of LDL cholesterol.
Source Information
Department of Surgery, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden.
This article has been cited by other articles:
Parini, P., Gustafsson, U., Davis, M. A., Larsson, L., Einarsson, C., Wilson, M., Rudling, M., Tomoda, H., Omura, S., Sahlin, S., Angelin, B., Rudel, L. L., Eriksson, M.
(2008). Cholesterol Synthesis Inhibition Elicits an Integrated Molecular Response in Human Livers Including Decreased ACAT2. Arterioscler. Thromb. Vasc. Bio.
28: 1200-1206
[Abstract][Full Text]
Berkenstam, A., Kristensen, J., Mellstrom, K., Carlsson, B., Malm, J., Rehnmark, S., Garg, N., Andersson, C. M., Rudling, M., Sjoberg, F., Angelin, B., Baxter, J. D.
(2008). From the Cover: The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl. Acad. Sci. USA
105: 663-667
[Abstract][Full Text]
Sirtori, C. R.
(2006). HDL and the progression of atherosclerosis: new insights. Eur Heart J Suppl
8: F4-F9
[Abstract][Full Text]
Brousseau, M. E., Diffenderfer, M. R., Millar, J. S., Nartsupha, C., Asztalos, B. F., Welty, F. K., Wolfe, M. L., Rudling, M., Bjorkhem, I., Angelin, B., Mancuso, J. P., Digenio, A. G., Rader, D. J., Schaefer, E. J.
(2005). Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion. Arterioscler. Thromb. Vasc. Bio.
25: 1057-1064
[Abstract][Full Text]
Lind, S., Rudling, M., Ericsson, S., Olivecrona, H., Eriksson, M., Borgstrom, B., Eggertsen, G., Berglund, L., Angelin, B.
(2004). Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans. Arterioscler. Thromb. Vasc. Bio.
24: 349-356
[Abstract][Full Text]
Matthan, N. R., Giovanni, A., Schaefer, E. J., Brown, B. G., Lichtenstein, A. H.
(2003). Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J. Lipid Res.
44: 800-806
[Abstract][Full Text]
Hiyoshi, H., Yanagimachi, M., Ito, M., Yasuda, N., Okada, T., Ikuta, H., Shinmyo, D., Tanaka, K., Kurusu, N., Yoshida, I., Abe, S., Saeki, T., Tanaka, H.
(2003). Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J. Lipid Res.
44: 128-135
[Abstract][Full Text]
Rudling, M., Angelin, B., Stahle, L., Reihner, E., Sahlin, S., Olivecrona, H., Bjorkhem, I., Einarsson, C.
(2002). Regulation of Hepatic Low-Density Lipoprotein Receptor, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, and Cholesterol 7{alpha}-Hydroxylase mRNAs in Human Liver. J. Clin. Endocrinol. Metab.
87: 4307-4313
[Abstract][Full Text]
Bjorkhem, I., Araya, Z., Rudling, M., Angelin, B., Einarsson, C., Wikvall, K.
(2002). Differences in the Regulation of the Classical and the Alternative Pathway for Bile Acid Synthesis in Human Liver. NO COORDINATE REGULATION OF CYP7A1 AND CYP27A1. J. Biol. Chem.
277: 26804-26807
[Abstract][Full Text]
Kornerup, K., Nordestgaard, B. G., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, K. S., Jensen, J. S.
(2002). Transvascular Low-Density Lipoprotein Transport in Patients With Diabetes Mellitus (Type 2): A Noninvasive In Vivo Isotope Technique. Arterioscler. Thromb. Vasc. Bio.
22: 1168-1174
[Abstract][Full Text]
Miettinen, T. A., Strandberg, T. E., Gylling, H., Group, f. t. F. I. o. t. S. S. S. S.
(2000). Noncholesterol Sterols and Cholesterol Lowering by Long-Term Simvastatin Treatment in Coronary Patients : Relation to Basal Serum Cholestanol. Arterioscler. Thromb. Vasc. Bio.
20: 1340-1346
[Abstract][Full Text]
Lanzarotto, F, Panarotto, B, Sorbara, R, Panteghini, M, Pagani, F, Sosta, S, Lanzini, A
(1999). Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. Gut
44: 552-556
[Abstract][Full Text]
Higaki, J., Hara, S., Takasu, N., Tonda, K., Miyata, K., Shike, T., Nagata, K., Mizui, T.
(1998). Inhibition of Ileal Na+/Bile Acid Cotransporter by S-8921 Reduces Serum Cholesterol and Prevents Atherosclerosis in Rabbits. Arterioscler. Thromb. Vasc. Bio.
18: 1304-1311
[Abstract][Full Text]
Berger, G. M. B., Pegoraro, R. J., Patel, S. B., Naidu, P., Rom, L., Hidaka, H., Marais, A. D., Jadhav, A., Naoumova, R. P., Thompson, G. R.
(1998). HMG-CoA reductase is not the site of the primary defect in phytosterolemia. J. Lipid Res.
39: 1046-1054
[Abstract][Full Text]
Berglund, L., Witztum, J. L., Galeano, N. F., Khouw, A. S., Ginsberg, H. N., Ramakrishnan, R.
(1998). Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. J. Lipid Res.
39: 913-924
[Abstract][Full Text]
Cuchel, M., Schaefer, E. J., Millar, J. S., Jones, P. J.H., Dolnikowski, G. G., Vergani, C., Lichtenstein, A. H.
(1997). Lovastatin Decreases De Novo Cholesterol Synthesis and LDL Apo B-100 Production Rates in Combined-Hyperlipidemic Males. Arterioscler. Thromb. Vasc. Bio.
17: 1910-1917
[Abstract][Full Text]
Previous
